Amorim Moreira AlvesGTeranishiMTeixeira de Castro Gonçalves OrtegaAC, et al. (2025) Mechanisms of GLP-1 in modulating craving and addiction: Neurobiological and translational insights. Medical Sciences (Basel, Switzerland)13(3): 136.
2.
BettadapuraSDowlingKJablonK, et al. (2025) Changes in food preferences and ingestive behaviors after glucagon-like peptide-1 analog treatment: Techniques and opportunities. International Journal of Obesity (2005)49(3): 418–426.
3.
DiasDDVasconcelosARSouzaACR, et al. (2025) Nutritional approaches to enhance GLP-1 analogue therapy in obesity: A narrative review. Obesities5(4): 88.
4.
FitchAGigliottiLBaysHE (2025) Application of nutrition interventions with GLP-1 based therapies: A narrative review of the challenges and solutions. Obesity Pillars16: 100205.
5.
Gonzalez-RellanMJDruckerDJ (2025) The expanding benefits of GLP-1 medicines. Cell Reports. Medicine6(7): 102214.
6.
HildebrandSPfeiferA (2025) The obesity pandemic and its impact on non-communicable disease burden. Pflugers Archiv: European Journal of Physiology477(5): 657–668.
7.
KerlikowskyFKrämerKEggersdorferM, et al. (2025) GLP-1 receptor agonists—Good for body weight, bad for micronutrient status?Current Developments in Nutrition9(11): 107587.
8.
MozaffarianDAgarwalMAggarwalM, et al. (2025) Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity (Silver Spring, Md.)33(8): 1475–1503.
9.
QiQYDCoxAMcNeilS, et al. (2024) Obesity medications: A narrative review of current and emerging agents. Osteoarthritis and Cartilage Open6(2): 100472.
10.
SibalRBalamuruganGLangleyJ, et al. (2025) Macronutrient, micronutrient supplementation and monitoring for patients on GLP-1 agonists: Can we learn from metabolic and bariatric surgery?Nutrients17(23): 3659.
11.
UllahMITamannaS (2025) Obesity: Clinical impact, pathophysiology, complications, and modern innovations in therapeutic strategies. Medicines12(3): 19.
12.
UrbinaJSalinas-RuizLEValencianoC, et al. (2026) Micronutrient and nutritional deficiencies associated with GLP-1 receptor agonist therapy: A narrative review. Clinical Obesity16(1): e70070.
13.
WildingJPHBatterhamRLCalannaS, et al. ; Step 1 Study Group (2021) Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine384(11): 989–1002.
ZhengZZongYMaY, et al. (2024) Glucagon-like peptide-1 receptor: Mechanisms and advances in therapy. Signal Transduction and Targeted Therapy9(1): Article 234.
